F. Hoffmann-La Roche AG, Amgen Inc., Merck & Co., Inc., are dominating the Global Glioblastoma Multiforme Treatment Market in 2021

The Global Glioblastoma Multiforme Treatment Market is expected to grow with a CAGR of 8.1% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-glioblastoma-multiforme-treatment-market

The global glioblastoma multiforme treatment market is a highly consolidated market, which includes specific number of key players. The market has witnessed increased strategic developments owing to favourable market scenario.  

The major players dealing in global glioblastoma multiforme treatment market are introducing strong range of products provider along with launching new products and adopting strategic initiatives such as acquisition, agreement, business expansion, award and recognition into the market. This helped companies to maximize the sales with enhanced product portfolio.  

For instance:

  • In April 2022, Elekta and GE Healthcare announced that they had signed a global commercial collaboration agreement in the field of radiation oncology, enabling them to provide hospitals a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy. This partnership will allow the companies to jointly promote solutions for each cancer center’s needs
  • In July 2019, Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) is available in the United States (U.S.). This launch will enhance the sales of the product in the region

F. Hoffmann-La Roche AG is the dominating player in the global glioblastoma multiforme treatment market. The other key players existing in the market are Amgen Inc., Merck & Co., Inc., Pfizer Inc., Varian Medical Systems, Inc.  (A subsidiary of Siemens Healthcare), ZEISS International, Amneal Pharmaceuticals LLC, Elekta, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Eckert & Ziegler, Accord Healthcare, Angiochem, ANI Pharmaceuticals, Inc., Arbor Pharmaceuticals, LLC.  (A Subsidiary of Azurity Pharmaceuticals, Inc.), AstraZeneca, Cantex Pharmaceuticals, Inc., CELON LABS, Diffusion Pharmaceuticals Inc., EnGeneIC, ERC.SA., Genenta science, Jazz Pharmaceuticals, Inc., Loxo Oncology (A Subsidiary of Eli Lilly), Novartis AG, VBL THERAPEUTICS, Viatris Inc., and Zydus Pharmaceuticals, Inc., among others.

F. Hoffmann-La Roche AG

F. Hoffmann-La Roche AG is headquartered in Baden-Wurttemberg, Switzerland, and was founded in the year 1898. The company focuses on development of innovative medicines and diagnostic tests that help patients live longer, and better lives. The various products of the company include oncology, immunology, ophthalmology, infectious diseases, cardiometabolism, neuroscience, others out of which oncology is the market-focused category.    

The company has a wide presence across Americas, Europe, Africa, Asia, Oceania. In addition, the company also generates its revenue from various subsidiaries including Genentech (U.S), Chugai Pharmaceutical Co. (Japan), ROCHE HOLDING (UK) LIMITED (UK), Roche (Philippines) Inc. (Philippines), Roche Chile Limitada (Chile), among others.

Amgen Inc.

Amgen Inc. is headquartered in Carlifonia, U.S., and was founded in the year 1980. The company is focused on transforming science and biotechnology into therapies that have the power to restore health or save lives. The various products of the company include Cardiovascular Disease, Oncology, Bone Health, Neuroscience, Nephrology and Inflammation in which Oncology is a market-focused category.

For instance,

  • In July 2019, Amgen and Allergan plc announced that MVASI (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab) is available in the United States (U.S.). This launch will enhance the sales of the product in the region

The company has a presence across North America, Asia Pacific, South America, Europe, Middle East and Africa. In addition, the company also generates its revenue from various subsidiaries including Amgen (Europe) GmbH Switzerland, Amgen Fremont Inc.  (Delaware), Amgen Global Finance B.V.  (Netherlands), Amgen GmbH (Germany), Amgen Ilaç Ticaret Limited Şirketi  (Turkey), Amgen Manufacturing, Limited  (Bermuda), Amgen Research (Munich) GmbH  Germany, Amgen Rockville, Inc.  (Delaware), Amgen S.A.S.  (France).

Merck & Co., Inc.  

Merck & Co., Inc.  is headquartered in New Jersey, U.S. and was founded in the year 1953. The company is focused on development of innovative medicines and diagnostics tests that help patients live longer, and better lives. The various product categories of the company include Oncology, Vaccines, Infectious Diseases, COVID -19, Cardio- Metabolic Disorders in which Oncology is the market focused category.  

For instance,

  • In September 2020, Merck & Co., Inc.  announced two new strategic oncology collaborations with Seattle Genetics, Inc. The companies will globally develop and commercialize drugs such as Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate (ADC) targeting LIV-1, which is currently in phase 2 clinical trials for breast cancer and other solid tumors. This collaboration will ensure increasing R&D operations in the field of oncology.

The company has a presence across Americas, Europe, Asia-Pacific, Middle East & Africa. In addition, the company also generates its revenue from various subsidiaries including Merck Sharp & Dohme (Australia) Pty. Ltd (Australia), Merck Sharp & Dohme (Malaysia) Sdn. Bhd. (Malaysia), MSD Finland Oy (Finland), Merck Sharp & Dohme B.V. (Netherlands), Merck Sharp & Dohme (Sweden) A.B. (Sweden) and others.